Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

Related Articles by Review for PubMed (Select 14761703)

1.

Hallucinogens.

Nichols DE.

Pharmacol Ther. 2004 Feb;101(2):131-81. Review.

PMID:
14761703
2.

Nerve terminal effects of indoleamine psychotomimetics on 5-hydroxytryptamine.

Halaris AE.

Neurosci Biobehav Rev. 1982 Winter;6(4):483-7. Review.

PMID:
6294571
3.

Hallucinogens, serotonin and obsessive-compulsive disorder.

Delgado PL, Moreno FA.

J Psychoactive Drugs. 1998 Oct-Dec;30(4):359-66. Review.

PMID:
9924841
4.

Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.

Korff S, Harvey BH.

Psychiatr Clin North Am. 2006 Jun;29(2):371-90. Review.

PMID:
16650714
5.

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Meltzer HY, Huang M.

Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Review.

PMID:
18772033
6.
7.

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.

Halberstadt AL, Geyer MA.

Neuropharmacology. 2011 Sep;61(3):364-81. doi: 10.1016/j.neuropharm.2011.01.017. Epub 2011 Jan 20. Review.

8.

Psychedelics and schizophrenia.

González-Maeso J, Sealfon SC.

Trends Neurosci. 2009 Apr;32(4):225-32. doi: 10.1016/j.tins.2008.12.005. Epub 2009 Mar 5. Review.

PMID:
19269047
9.

Serotonin research: contributions to understanding psychoses.

Geyer MA, Vollenweider FX.

Trends Pharmacol Sci. 2008 Sep;29(9):445-53. doi: 10.1016/j.tips.2008.06.006. Review.

PMID:
19086254
10.

Animal models of serotonergic psychedelics.

Hanks JB, González-Maeso J.

ACS Chem Neurosci. 2013 Jan 16;4(1):33-42. doi: 10.1021/cn300138m. Epub 2012 Sep 24. Review.

11.

Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?

Landolt HP, Wehrle R.

Eur J Neurosci. 2009 May;29(9):1795-809. doi: 10.1111/j.1460-9568.2009.06718.x. Epub 2009 Apr 28. Review.

PMID:
19473234
12.

Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.

Bubar MJ, Cunningham KA.

Prog Brain Res. 2008;172:319-46. doi: 10.1016/S0079-6123(08)00916-3. Review.

PMID:
18772040
13.

Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.

Terry AV Jr, Buccafusco JJ, Wilson C.

Behav Brain Res. 2008 Dec 16;195(1):30-8. doi: 10.1016/j.bbr.2007.12.006. Epub 2008 Feb 1. Review.

PMID:
18241938
14.

Agonist-trafficking and hallucinogens.

González-Maeso J, Sealfon SC.

Curr Med Chem. 2009;16(8):1017-27. Review.

PMID:
19275609
15.

Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence.

Bubar MJ, Cunningham KA.

Curr Top Med Chem. 2006;6(18):1971-85. Review.

PMID:
17017968
16.

Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.

Bogenschutz MP, Pommy JM.

Drug Test Anal. 2012 Jul-Aug;4(7-8):543-55. doi: 10.1002/dta.1376. Epub 2012 Jul 4. Review.

PMID:
22761106
17.

The pharmacology of lysergic acid diethylamide: a review.

Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A.

CNS Neurosci Ther. 2008 Winter;14(4):295-314. doi: 10.1111/j.1755-5949.2008.00059.x. Review.

PMID:
19040555
18.

Serotonin and hallucinogens.

Aghajanian GK, Marek GJ.

Neuropsychopharmacology. 1999 Aug;21(2 Suppl):16S-23S. Review.

19.

Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK.

Green AR.

Br J Pharmacol. 2008 Aug;154(8):1583-99. doi: 10.1038/bjp.2008.207. Epub 2008 May 26. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk